Apyx Medical Corporation Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

Apyx Medical (Nasdaq: APYX) announced on November 17, 2025 that it has commenced a proposed underwritten public offering of common stock or common stock equivalents, subject to market conditions.

Lucid Capital Markets is sole book-running manager. The offering will be made from a shelf registration on Form S-3 (File No. 333-268532) declared effective December 2, 2022; a preliminary prospectus supplement and prospectus will be filed with the SEC and posted at www.sec.gov when available. The company cautioned there is no assurance the offering will be completed on the anticipated terms.

Company products include Renuvion, AYON Body Contouring System (FDA-cleared), and J-Plasma, supported by more than 90 clinical documents.

Insights

Capital Markets Strategist

Apyx has commenced an underwritten offering of common stock; timing, size and terms remain undetermined.

Apyx Medical Corporation announced on Nov 17, 2025 that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is being managed by Lucid Capital Markets as sole book‑running manager and is being made under an existing shelf registration on Form S-3 declared effective on Dec 2, 2022. The company states the offering is subject to market conditions and that there is no assurance it will be completed or as to the final size or terms.

The immediate business mechanism is straightforward: the company is seeking to raise equity capital via a registered shelf sale of common stock or equivalents. Key dependencies and risks are explicit in the release: the offering may not occur, final size and terms are unknown, and any forward‑looking projections are qualified by the company’s cautionary statement. The announcement does not disclose the proceeds target, use of proceeds, or dilution metrics.

Concrete items to watch include the filing of the preliminary prospectus supplement with the SEC (which will show offering size, price range, and use of proceeds), the actual pricing and whether the offering closes, and any subsequent updates to the company’s filings (including Form 8‑K or amendments to the S‑3). Expect these items to appear within the near term once market conditions are set and the prospectus is filed.

CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Lucid Capital Markets is acting as the sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange Commission (“SEC”) on November 22, 2022, and declared effective by the SEC on December 2, 2022.

A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Investor Relations Contact:

Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com

About Apyx Medical Corporation:

Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma^® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System™ is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, statements regarding the Company’s anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance.

Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

FAQ

What did Apyx Medical (APYX) announce on November 17, 2025 about a stock offering?

Apyx announced it commenced a proposed underwritten public offering of common stock or equivalents, subject to market conditions.

Who is the book-running manager for the APYX November 2025 offering?

Lucid Capital Markets is acting as the sole book-running manager for the offering.

Where can investors find the APYX preliminary prospectus for the November 2025 offering?

The preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and available at www.sec.gov when filed.

Does the November 17, 2025 Apyx press release state the size or price of the APYX offering?

No; the press release states the offering is subject to market conditions and does not disclose the size or terms.

What Apyx products were highlighted in the November 17, 2025 announcement (APYX)?

The release highlights Renuvion, the FDA-cleared AYON Body Contouring System, and J-Plasma, noting more than 90 clinical documents support Renuvion and J-Plasma.

Is the November 17, 2025 Apyx offering an immediate offer to buy or sell securities?

No; the company said the press release does not constitute an offer to sell or solicitation to buy any securities in any jurisdiction where unlawful.